We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+7.52%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$126M
AUM Growth
+$6.95M
Cap. Flow
-$1.04M
Cap. Flow %
-0.83%
Top 10 Hldgs %
37.72%
Holding
74
New
9
Increased
25
Reduced
7
Closed
17

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$3.42M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$1.55M
3
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$1.03M
4
PCRX icon
Pacira BioSciences
PCRX
+$949K
5
ARRY
Array Biopharma Inc
ARRY
+$886K

Top Sells

Rank Stock Value
1
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$4.15M
2
PCYC
PHARMACYCLICS INC
PCYC
+$3.48M
3
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$1.73M
4
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$912K
5
TENX icon
Tenax Therapeutics
TENX
+$812K

Sector Composition

Rank Sector Weight
1 Healthcare 82.86%
2 Miscellaneous 16.89%
3 Financials 0.25%
4 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCPT
1
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$5.34M 4.23%
28,124
+2,445
+10% +$404K
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$5.05M 4%
104,339
-6,711
-6% -$277K
BMRN icon
3
BioMarin Pharmaceuticals
BMRN
$12.6B
$4.91M 3.89%
35,899
+3,354
+10% +$416K
BIB icon
4
ProShares Ultra NASDAQ Biotechnology
BIB
$105M
$4.84M 3.83%
53,568
+18,000
+51% +$1.55M
ILMN icon
5
Illumina
ILMN
$34.4B
$4.68M 3.71%
22,052
+866
+4% +$169K
CLVS
6
DELISTED
Clovis Oncology, Inc.
CLVS
$4.61M 3.65%
52,400
-3,588
-6% -$307K
NKTR icon
7
Nektar Therapeutics
NKTR
$2.55B
$4.6M 3.65%
24,531
+2,154
+10% +$371K
ALKS icon
8
Alkermes
ALKS
$8.2B
$4.57M 3.62%
71,022
+8,476
+14% +$519K
BIIB icon
9
Biogen
BIIB
$32.7B
$4.55M 3.6%
11,254
+1,923
+21% +$772K
REGN icon
10
Regeneron Pharmaceuticals
REGN
$83.2B
$4.47M 3.54%
8,759
+9
+0.1% +$4.39K
CELG
11
DELISTED
Celgene Corp
CELG
$4.44M 3.52%
38,375
+5,086
+15% +$581K
INCY icon
12
Incyte
INCY
$25.9B
$4.36M 3.46%
41,873
-1,809
-4% -$187K
VRTX icon
13
Vertex Pharmaceuticals
VRTX
$139B
$4.36M 3.45%
35,276
+2,471
+8% +$311K
ALNY icon
14
Alnylam Pharmaceuticals
ALNY
$31.7B
$4.19M 3.32%
34,979
-2,409
-6% -$288K
MDVN
15
DELISTED
MEDIVATION, INC.
MDVN
$3.92M 3.11%
68,688
+7,194
+12% +$443K
CPHD
16
DELISTED
Cepheid Inc
CPHD
$3.89M 3.08%
63,635
+8,942
+16% +$510K
ALXN
17
DELISTED
Alexion Pharmaceuticals
ALXN
$3.88M 3.07%
21,474
-557
-3% -$96.1K
IONS icon
18
Ionis Pharmaceuticals
IONS
$10.4B
$3.81M 3.02%
66,208
+5,296
+9% +$337K
MTD icon
19
Mettler-Toledo International
MTD
$28.2B
$3.76M 2.97%
11,000
+1,564
+17% +$515K
QGENF
20
DELISTED
QIAGEN NV
QGENF
$3.47M 2.75%
140,000
+17,276
+14% +$428K
TECH icon
21
Bio-Techne
TECH
$11.4B
$3.35M 2.65%
136,000
+12,332
+10% +$308K
PCRX icon
22
Pacira BioSciences
PCRX
$1.03B
$3.32M 2.63%
47,000
+12,051
+34% +$949K
AZN icon
23
AstraZeneca
AZN
$255B
$3.19M 2.52%
+50,000
New +$3.42M
ARRY
24
DELISTED
Array Biopharma Inc
ARRY
$2.31M 1.83%
320,000
+120,000
+60% +$886K
HOLX
25
DELISTED
Hologic
HOLX
$1.83M 1.45%
48,000
-2,000
-4% -$70K
1
2 3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q2 2015 Portfolio in Review

As of Q2 2015, Opus Point Partners Management held 74 positions worth $126M, up 5.8% from $119M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Opus Point Partners Management's Q2 2015 filing shows 9 new, 25 increased, 7 reduced and 17 closed positions. Its largest new stake was AstraZeneca: 50,000 shares worth $3.19M. The largest sale was SALIX PHARMACEUTICALS LTD DEL, an estimated $4.15M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 78% a quarter earlier, followed by Miscellaneous and Financials.

  • Opus Point Partners Management's largest Q2 2015 buy was AstraZeneca: 50,000 shares worth $3.19M.
  • Opus Point Partners Management added most to ProShares Ultra NASDAQ Biotechnology in Q2 2015, an estimated $1.55M increase.
  • Opus Point Partners Management's biggest Q2 2015 reduction was Clovis Oncology, Inc., cutting an estimated $307K.
  • Opus Point Partners Management fully exited SALIX PHARMACEUTICALS LTD DEL in Q2 2015, selling an estimated $4.15M.
  • Opus Point Partners Management's ten largest holdings make up 38% of its $126M portfolio in Q2 2015.
  • Opus Point Partners Management opened 9 new positions and closed 17 in Q2 2015.
  • Opus Point Partners Management's portfolio value rose 5.8% quarter-over-quarter to $126M.

Based on Opus Point Partners Management's 13F filing for Q2 2015, filed 14 Aug 2015.